Kallikrein 11 Antikörper (AA 68-82)

Produktnummer ABIN636296

Der Kaninchen Polyklonal anti-Kallikrein 11 Antikörper wird verwendet zum Nachweis von Kallikrein 11 in Proben von Human. Er wurde validiert für WB.

Kurzübersicht für Kallikrein 11 Antikörper (AA 68-82) (ABIN636296)

Target: Kallikrein 11 (KLK11)

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Kallikrein 11 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Produktdetails anti-Kallikrein 11 Antikörper

Bindungsspezifität: AA 68-82

Kreuzreaktivität: Maus, Ratte (Rattus)

Kreuzreaktivität (Details): This antibodys immunogen shares 86 % sequence identity with the Mouse, and rat homologs.

Aufreinigung: Affinity chromatography purified

Immunogen: KLK11 antibody was raised in rabbit using AA 68-82 [YIVHLGQHNLQKEEG] of the 35 kDa human hippostasin/KLK11 protein as the immunogen.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB: 1:500-1:1,000
Optimal conditions should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: Lot specific

Buffer: Affinity purified IgG supplied in PBS with 0.02 % NaN3.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium Azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Handhabung: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store at 4 °C for short term storage. Aliquot and store at -20 °C for long term storage.

Details zu Kallikrein 11

Target: Kallikrein 11 (KLK11)

Andere Bezeichnung: KLK11

Hintergrund: Hippostasin, also known as KLK11, is a kallikrein-like serine protease, which has two alternatively spliced isoforms, brain-type and prostate-type. Hippostasin plays a role in the prostate, including reproductive and/or tumorigenic functions. Elevated serum levels of hK11 were found in 70% of women with ovarian cancer and in 60% of men with prostate cancer.

Pathways: Komplementsystem